IPC
GALT icon

Independent Portfolio Consultants’s Galectin Therapeutics GALT Stock Holding History

Independent Portfolio Consultants’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-570
Closed -$3K – 821
2014
Q3 		$3K Sell
570
-755
-57% -$5.88K ﹤0.01% 803
2014
Q2 		$18K Buy
+1,325
New +$16.5K 0.01% 783

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Independent Portfolio Consultants's GALT Position: Q4 2014 in Review

Independent Portfolio Consultants sold out of Galectin Therapeutics (GALT) in Q4 2014, closing a stake of 570 shares — an estimated $3K sold.

Independent Portfolio Consultants first reported a position in GALT in Q2 2014 and held it in 2 quarters. The position peaked at $18K in Q2 2014. 62 funds tracked by Wall St. Rank hold GALT as of Q4 2014.

  • Independent Portfolio Consultants reported no remaining Galectin Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Independent Portfolio Consultants sold 570 Galectin Therapeutics shares in Q4 2014, an estimated $3K.
  • Independent Portfolio Consultants first reported a position in Galectin Therapeutics in Q2 2014 and held it in 2 quarters.
  • Independent Portfolio Consultants's Galectin Therapeutics position peaked at $18K in Q2 2014.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2014.

Based on Independent Portfolio Consultants's 13F filing for Q4 2014, filed 17 Feb 2015.